UBS Group
IDYA icon

UBS Group’s IDEAYA Biosciences IDYA Stock Holding History

UBS Group’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.5M Sell
656,721
-105,827
-14% -$3.24M ﹤0.01% 2469
2026
Q1 		$25.4M Sell
762,548
-323,084
-30% -$10.8M ﹤0.01% 2337
2025
Q4 		$37.5M Buy
1,085,632
+29,055
+3% +$926K 0.01% 1944
2025
Q3 		$28.7M Buy
1,056,577
+304,672
+41% +$7.37M ﹤0.01% 2176
2025
Q2 		$15.8M Buy
751,905
+301,758
+67% +$5.79M ﹤0.01% 2624
2025
Q1 		$7.37M Buy
450,147
+31,662
+8% +$675K ﹤0.01% 3376
2024
Q4 		$10.8M Buy
418,485
+278,938
+200% +$7.9M ﹤0.01% 2957
2024
Q3 		$4.42M Sell
139,547
-89,258
-39% -$3.38M ﹤0.01% 3203
2024
Q2 		$8.03M Sell
228,805
-14,244
-6% -$564K ﹤0.01% 2416
2024
Q1 		$10.7M Buy
243,049
+92,347
+61% +$3.97M ﹤0.01% 2217
2023
Q4 		$5.36M Buy
150,702
+94,167
+167% +$2.81M ﹤0.01% 2713
2023
Q3 		$1.53M Buy
56,535
+47,486
+525% +$1.2M ﹤0.01% 3706
2023
Q2 		$213K Sell
9,049
-47,405
-84% -$975K ﹤0.01% 5436
2023
Q1 		$775K Sell
56,454
-58,149
-51% -$969K ﹤0.01% 4331
2022
Q4 		$2.08M Buy
114,603
+99,753
+672% +$1.68M ﹤0.01% 3356
2022
Q3 		$222K Buy
14,850
+10,244
+222% +$133K ﹤0.01% 4999
2022
Q2 		$64K Sell
4,606
-71,765
-94% -$798K ﹤0.01% 5740
2022
Q1 		$854K Sell
76,371
-40,996
-35% -$604K ﹤0.01% 4266
2021
Q4 		$2.77M Buy
117,367
+72,996
+165% +$1.7M ﹤0.01% 3441
2021
Q3 		$1.13M Buy
44,371
+21,160
+91% +$494K ﹤0.01% 4088
2021
Q2 		$487K Buy
23,211
+10,846
+88% +$223K ﹤0.01% 4758
2021
Q1 		$291K Buy
12,365
+11,506
+1,339% +$222K ﹤0.01% 5225
2020
Q4 		$12K Buy
859
+601
+233% +$8.14K ﹤0.01% 7343
2020
Q3 		$3K Sell
258
-3,557
-93% -$44.1K ﹤0.01% 7533
2020
Q2 		$54K Buy
3,815
+3,113
+443% +$24.5K ﹤0.01% 5787
2020
Q1 		$3K Buy
+702
New +$4.97K ﹤0.01% 7490
2019
Q4 		– Sell
-3,023
Closed -$27K – 8248
2019
Q3 		$27K Buy
+3,023
New +$23.1K ﹤0.01% 6547

Other funds holding IDYA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

UBS Group's IDYA Position: Q2 2026 in Review

UBS Group reduced its IDEAYA Biosciences (IDYA) stake by 14% in Q2 2026, selling an estimated $3.24M and leaving 656,721 shares worth $24.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2469.

UBS Group first reported a position in IDYA in Q3 2019 and has held it in 27 quarters since. The position peaked at $37.5M in Q4 2025. 285 funds tracked by Wall St. Rank hold IDYA as of Q2 2026.

  • UBS Group held 656,721 shares of IDEAYA Biosciences worth $24.5M as of Q2 2026.
  • UBS Group sold 105,827 IDEAYA Biosciences shares in Q2 2026, an estimated $3.24M.
  • IDEAYA Biosciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2469 holding.
  • UBS Group first reported a position in IDEAYA Biosciences in Q3 2019 and has held it in 27 quarters since.
  • UBS Group's IDEAYA Biosciences position peaked at $37.5M in Q4 2025.
  • 285 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.